Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Venus RemediesNSE:VENUSREM +4.82%58 Interest Coverage is No Debt (1) as of Jun. 2026, which is 100% below its 10-year median of 144.34. GuruFocus rates NSE:VENUSREM with a GF Score™ of 58/100 and a GF Value™ of ₹466.33 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 687 Drug Manufacturers companies, Venus Remedies ranks better than 94.91% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Venus Remedies's
Operating Income
for the
three
months ended in Jun. 2026 was ₹274 Mil. Venus Remedies's Interest Expense for the
three
months ended in Jun. 2026 was ₹0 Mil.
Venus Remedies has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Venus Remedies Ltd has enough cash to cover all of its debt. Its financial situation is stable.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Venus Remedies's Interest Coverage or its related term are showing as below:
NSE:VENUSREM'
s Interest Coverage Range Over the Past 10 Years
Min: 0.17 Med: 144.34 Max: 3040.25
Current: 2908.25
NSE:VENUSREM's Interest Coverage is ranked better than 94.91% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs NSE:VENUSREM: 2908.25
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Venus Remedies Interest Coverage Related Terms
Venus Remedies Interest Coverage Historical Data
* Premium members only.
The historical data trend for Venus Remedies's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:VENUSREM vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Venus Remedies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Remedies Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venus Remedies's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Venus Remedies's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Venus Remedies (NSE:VENUSREM) has a Interest Coverage of No Debt (1) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Venus Remedies and its competitors. This is 99% below median its historical median of 144.34. Over the past decade, Venus Remedies' Interest Coverage has ranged from 0.17 to 3,040.25. According to the industry distribution chart, Venus Remedies ranks #35 out of 687 companies in the Drug Manufacturers industry, placing it in the top 5.1%.
Is Venus Remedies' Interest Coverage too high?
Venus Remedies' current Interest Coverage of No Debt (1) is 99% below median its 10-year median of 144.34. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 3,040.25. Based on the distribution chart, Venus Remedies ranks #35 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Venus Remedies has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Venus Remedies ranks #35 out of 687 companies for Interest Coverage. This places Venus Remedies in the top 5% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Historically, Venus Remedies' own Interest Coverage has ranged from 0.17 to 3,040.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Venus Remedies and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Remedies's current Interest Coverage is No Debt (1), which is 99% below median its own 10-year median of 144.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (NSE:VENUSREM) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹466.33, compared to a current price of ₹1,775.50 — trading 280.7% above its estimated fair value. The current Interest Coverage is No Debt (1), which is 99% below median its 10-year median of 144.34. Venus Remedies' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Venus Remedies (NSE:VENUSREM), the current Interest Coverage is No Debt (1) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Remedies (NSE:VENUSREM) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued.
The current stock price of ₹1,775.50 is trading 280.7% above its estimated GF Value™ of ₹466.33.
GuruFocus considers Venus Remedies to be Significantly Overvalued.
Key valuation signals for NSE:VENUSREM:
Interest Coverage: No Debt (1) (99% below median its 10-year median of 144.34)
GF Value™: ₹466.33 vs. price of ₹1,775.50 (280.7% above fair value)
No single metric tells the full story. See the NSE:VENUSREM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
58GF Score
Get the complete analysis for NSE:VENUSREM
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VENUSREM has been successfully added to your 
